Alex Philippidis is a Senior Business Editor for Genetic Engineering & Biotechnology News. With a focus on the biotechnology and pharmaceutical industries, Alex covers a wide range of topics including drug development, precision medicine, gene therapy, and emerging technologies. His work has also been featured in Inside Precision Medicine, showcasing his expertise in the field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
International
Alex Philippidis mainly covers healthcare and pharmaceutical industry, focusing on investment analysis, private sector announcements, and press releases. He would likely be interested in receiving pitches related to breakthroughs in drug development, acquisitions within the biopharmaceutical industry, advancements in gene therapy as well as the application of AI in healthcare.
Given his interest in citing data and investment analysis, he might appreciate pitches that provide substantial data-driven insights into trends or companies within the healthcare and pharmaceutical sectors. Additionally, pitches featuring exclusive access to company executives for interviews or providing unique perspectives on M&A activities could also resonate with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Alex Philippidis
A researcher loads PacBio's Revio™ long-read system for a sequencing run. PacBio shares plummeted 51% on Tuesday after the long-read sequencing giant reversed its earlier “guidance” forecast to investors for 5% operating expense growth this year, revealing instead plans to cut its annual operating expense run rate by $50 million to $75 million. [PacBio]
By: Alex Philippidis
Boehringer Ingelheim will apply Ochre Bio’s discovery platform to develop treatments for late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and other chronic liver diseases (CLDs), through a collaboration that could generate more than $1 billion for the British developer of RNA-based liver treatments.
By: Alex Philippidis
Companies take aim at the longtime delivery challenge associated with genetic medicines, by targeting tissues and cell types beyond the liver
By: Alex Philippidis
AI-based drug developer Xaira Therapeutics has been launched with more than $1 billion in capital and a self-described ambitious commitment to transform drug discovery and development by creating new and more effective treatments faster.
By: Alex Philippidis
Insilico Medicine is heading to the clinic with a treatment for methylthioadenosine phosphorylase (MTAP) deleted cancers.
By: Alex Philippidis
Investors and analysts are so used to bad news from Biogen (BIIB) that they seemingly didn’t know how to react when the biotech giant delivered better first quarter results than expected.
By: Alex Philippidis
Ono Pharmaceutical has agreed to acquire Deciphera Pharmaceuticals for $2.4 billion, in a deal designed to grow the buyer's oncology portfolio with
By: Alex Philippidis
Prime Medicine said it has gained FDA clearance for the first human trials of a prime editing therapy as the agency has approved an investigational new drug (IND) application for the company's first candidate to enter the clinic.
By: Alex Philippidis
CNS drug developers should prioritize the discovery of novel biomarkers through objective testing methods that go beyond genetics, says Linus Bio CEO Manish Arora, PhD.
By: Alex Philippidis
Novartis specialists on the production line of the company's recently-opened radioligand therapy (RLT) manufacturing facility in Indianapolis.
(833) 317-6278 
